Nationwide survey of palivizumab for respiratory syncytial virus prevention in japanese children with congenital heart disease

Pediatric Infectious Disease Journal

Volumn 27, Issue 12, 2008, Pages 1108-1109

  Saji, Tsutomu ^a,d   Nakazawa, Makoto ^b   Harada, Kensuke ^c  

^a TOHO UNIVERSITY   (Japan)

^b Southern Tohoku General Hospital and Southern Tohoku Research Institute for Neuroscience   (Japan)

^c NIHON UNIVERSITY   (Japan)

^d TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

congenital heart disease; guideline; nationwide survey; palivizumab; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CHILD; CHILD HOSPITALIZATION; CONGENITAL HEART DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; JAPANESE; MAJOR CLINICAL STUDY; PATIENT SELECTION; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRAL RESPIRATORY TRACT INFECTION; ANTIBIOTIC PROPHYLAXIS; CONGENITAL HEART MALFORMATION; FEMALE; HOSPITALIZATION; IMMUNOLOGY; INFANT; JAPAN; MALE; METHODOLOGY; NEWBORN; PRIMARY PREVENTION; STATISTICS; TREATMENT OUTCOME; VIROLOGY; VIRUS INFECTION;

ANTIBIOTIC PROPHYLAXIS; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; FEMALE; HEALTH SURVEYS; HEART DEFECTS, CONGENITAL; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; JAPAN; MALE; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; QUESTIONNAIRES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; TREATMENT OUTCOME;

EID: 58149392193     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181801d76     Document Type: Article

References (7)

1. Hall CB. Respiratory syncytial virus: what we know now. Contemp Pediatr. 1993;10:92-110.
2. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics. 1988; 82:199-203.
3. MacDonald NE, Hall CB, Suf?n SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in children with congenital heart disease. N Engl J Med. 1982;307:397-400.
4. Saji T, Nakazawa M, Harada K. Safety and ef?cacy of palivizumab prophylaxis in children with congenital heart disease. Pediatr Int. 2005; 47:397-403.
5. Nakazawa M, Saji T, Ichida F, Oyama K, Harada K, Kusuda S. Guideline for the use of palivizumab in infants and young children with congenital heart disease. Pediatr Int. 2004;48:190-193.
6. Feltes TF, Cabalka AK,Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically signi?cant congenital heart disease. J Pediatr. 2003;143: 532-540.
7. Infectious Disease Surveillance Center. Infectious Disease Weekly Report. Available at: http://idsc.nih.go.jp/idwr/index.html. Accessed March 12, 2008.